RCS - Intelligent Ultrasnd - Launch of Portable NeedleTrainer Plus

Intelligent UltrasoundAnnouncement

09/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240209:nRSI5605Ca&default-theme=true

RNS Number : 5605C  Intelligent Ultrasound Group PLC  09 February 2024

Intelligent Ultrasound launches portable NeedleTrainer Plus

 

PRESS RELEASE 9 February 2024: Intelligent Ultrasound Group plc (AIM: IUG),
the 'classroom to clinic' ultrasound company specialising in AI software and
simulation, is pleased to announce that it has launched a portable
NeedleTrainer Plus ultrasound-guided needling training simulator.

 

Aimed at training ultrasound-guided needling in military field-based
hospitals, as well as clinical networks outside major urban areas, the system
is packed in a robust, portable pelicase complete with a GE HealthCare Vscan
handheld ultrasound device.

 

NeedleTrainer is a first of its kind training simulator that uses a
retractable needle and virtual image overlays to simulate needling on a live
volunteer, using a live ultrasound scan. This enables trainees to develop
hand-eye coordination, optimum positioning, and accuracy in ultrasound-guided
interventional procedures in a realistic clinical environment with minimal
risk.

 

The system is part of a portfolio that includes Intelligent Ultrasound's
latest ScanNav™ Anatomy Peripheral Nerve Block, an AI technology that helps
healthcare professionals to identify and label anatomy in live ultrasound
images in preparation for ultrasound-guided regional anesthesia and analgesia.
The AI software automatically highlights the anatomy associated with the most
common peripheral nerve blocks.

 

Ultrasound-guided peripheral nerve block injections are increasingly used for
pain relief after surgery and trauma. Data from a study published in the
British Journal of Anaesthesia in September showed that, when ScanNav™
Anatomy PNB was available, there was a 40.4% relative increase in the number
of peripheral nerve blocks used in trauma cases, without a decrease in quality
of care.

 

Stuart Gall, CEO at Intelligent Ultrasound said:

"We hope this new version of NeedleTrainer will support clinicians in more
remote areas and help to open up additional markets for our simulators and AI
software in the US, UK and through our resellers around the world as we
continue to grow our classroom-to-clinic business."

 

ENDS

 

Enquiries:

 

 Intelligent Ultrasound Group plc   www.intelligentultrasound.com (http://www.intelligentultrasound.com)
 Stuart Gall, CEO                   Tel: +44 (0)29 2075 6534
 Helen Jones, CFO

 Cavendish Capital Markets Limited

 (Nominated advisor and broker)
 Giles Balleny (Corporate Finance)  Tel: +44 (0)20 7397 8900

 Nigel Birks (ECM)

 Dale Bellis (Sales)

 

  TB Cardew - PR Advisors   Intelligentultrasound@tbcardew.com (mailto:Intelligentultrasound@tbcardew.com)

  Ed Orlebar                          Tel: +44 (0)7738 724630
  Allison Connolly                                                    Tel: +44 (0)7587 453955
  Emma Pascoe-Watson                                                  Tel: +44 (0)7774 620415
  Jessica Pilling                                                     Tel: +44 (0)7918 584573

 

This is an RNS Reach announcement and the information contained is not
considered to have a significant impact on management's expectations of the
Group's performance. RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information required to
be notified under the AIM Rules for Companies, Market Abuse Regulation or
other regulation would be disseminated as an RNS regulatory announcement and
not on RNS Reach.

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,700 simulators have been sold to over 800 medical
institutions around the world.

 

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology are GE
HealthCare's SonoLyst software that is incorporated in their Voluson Expert
and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer
that teaches real-time ultrasound-guided needling and incorporates ScanNav
Anatomy PNB.

 

www.intelligentultrasound.com (http://www.intelligentultrasound.com/)

 

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the
FDA but is not available for sale in any other territory requiring government
approval for this type of product.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUWPPUPCGRR